{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:33:51Z","timestamp":1770914031707,"version":"3.50.1"},"reference-count":32,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2022YFA1103501"],"award-info":[{"award-number":["2022YFA1103501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Treatment for transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) has improved with anti-CD38 monoclonal antibodies. Among them, daratumumab, combined with standard therapies, has shown promising results in clinical trials. This meta-analysis consolidates evidence on the effectiveness and safety of daratumumab-based treatments for this patient group from all available randomized controlled trials (RCTs). Methods: We systematically searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and clinical trial registries from inception to September 2025 for phase II and III RCTs comparing daratumumab-containing regimens to non-daratumumab controls in TIE NDMM patients. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included minimal residual disease (MRD) negativity rate and adverse events (AEs). Heterogeneity was assessed using I2 statistics, and subgroup analyses were performed to explore potential sources of heterogeneity. Results: Six RCTs involving 2478 patients were included. Daratumumab-based regimens significantly improved PFS (hazard ratio [HR] = 0.544, 95% confidence interval [CI]: 0.483\u20130.612, p &lt; 0.001; I2 = 28.6%) and OS (HR = 0.693, 95% CI: 0.606\u20130.791, p &lt; 0.001; I2 = 30.6%). The MRD negativity rate was significantly higher with daratumumab (risk ratio [RR] = 2.322, 95% CI: 1.486\u20133.627, p &lt; 0.001). Furthermore, daratumumab-based regimens yielded a four-fold increase in the rate of sustained MRD negativity (\u226512 months) (RR = 3.999, 95% CI: 1.094\u20138.403, p &lt; 0.001). However, these regimens were associated with increased risks of serious adverse events (SAEs) (RR = 1.146, 95% CI: 1.064\u20131.233, p &lt; 0.001), overall grade 3\/4 AEs (RR = 1.075, 95% CI: 1.038\u20131.115, p &lt; 0.001), neutropenia, lymphopenia, infections, pneumonia, and fatal AEs. No significant differences were observed in thrombocytopenia or anemia. Conclusions: Daratumumab-based regimens significantly improve survival outcomes and the depth\/durability of treatment response in TIE NDMM patients, supporting their use as first-line therapy. However, the increased risk of specific AEs necessitates careful patient selection, proactive infection prevention, and vigilant monitoring. These findings provide robust evidence for clinical practice guidelines and underscore the need to balance efficacy with safety in this vulnerable population.<\/jats:p>","DOI":"10.3390\/cancers17203349","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:28:36Z","timestamp":1760696916000},"page":"3349","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7365-9214","authenticated-orcid":false,"given":"Chi","family":"Wang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyang","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilin","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhe","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Lan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.6004\/jnccn.2025.5008","article-title":"Updates to Management of Multiple Myeloma","volume":"23","author":"Callander","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_5","first-page":"16994","article-title":"New therapies in multiple myeloma: Benefits and limitations","volume":"135","author":"Jurczyszyn","year":"2025","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Offidani, M., Corvatta, L., More, S., Nappi, D., Martinelli, G., Olivieri, A., and Cerchione, C. (2021). Daratumumab for the Management of Newly Diagnosed and Relapsed\/Refractory Multiple Myeloma: Current and Emerging Treatments. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.624661"},{"key":"ref_7","first-page":"CD013487","article-title":"Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: A network meta-analysis","volume":"2019","author":"Piechotta","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1158\/1078-0432.CCR-24-4181","article-title":"FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma","volume":"31","author":"Sharma","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): Final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1080\/10428194.2025.2512031","article-title":"Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: An updated systematic review and meta-analysis based on randomized controlled trials","volume":"66","author":"Lin","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20406207251314289","DOI":"10.1177\/20406207251314289","article-title":"Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: A systematic review and meta-analysis","volume":"16","author":"Osama","year":"2025","journal-title":"Ther. Adv. Hematol."},{"key":"ref_20","first-page":"CD013595","article-title":"Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant","volume":"2024","author":"Langer","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-025-06303-3","article-title":"Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: Final analysis of the phase 3 OCTANS Study","volume":"104","author":"Fu","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","article-title":"Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study","volume":"23","author":"Fu","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/bloodadvances.2023012539","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16","volume":"8","author":"Mollee","year":"2024","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3026(25)00143-7","article-title":"Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): A phase 3, open-label, multicentre, randomised clinical trial","volume":"12","author":"Mateos","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E579","DOI":"10.1016\/j.clml.2020.04.004","article-title":"Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma","volume":"20","author":"Kamble","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nakamura, A., Suzuki, S., Kanasugi, J., Ejiri, M., Hanamura, I., Ueda, R., Seto, M., and Takami, A. (2021). Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910761"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3349\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:45:19Z","timestamp":1760697919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":32,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17203349"],"URL":"https:\/\/doi.org\/10.3390\/cancers17203349","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}